Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2015-12-31, filed 2016-02-08, with 31 holding rows worth $113,179,000.

Accession
0001172661-16-002454
Filed
2016-02-08
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2015

A holdings report, 31 entries on the cover page, a total value of $113,179,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $113,179,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BLUEPRINT MEDICINES CORP09627Y109COM412,500$10,865,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM143,011$8,338,000thousands by filing date
LOXO ONCOLOGY INC548862101COM251,500$7,155,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK321,023$6,700,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM145,000$6,570,000thousands by filing date
BLUEBIRD BIO INC09609G100COM100,000$6,422,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM96,500$6,265,000thousands by filing date
MYOKARDIA INC62857M105COM403,872$5,921,000thousands by filing date
GENOMIC HEALTH, INC.37244C101COM165,000$5,808,000thousands by filing date
ILLUMINA INC452327109COM30,000$5,758,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock60,000$5,648,000thousands by filing date
EPIZYME INC29428V104COM332,500$5,327,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK236,862$5,187,000thousands by filing date
ILLUMINA INC452327109COM20,000$3,839,000thousands by filing datecall
BIOGEN INC COM09062X103Stock9,000$2,757,000thousands by filing date
Foundation Medicine Inc350465100COM115,000$2,422,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM310,000$2,406,000thousands by filing date
Bristol-Myers Squibb Company110122108COM32,164$2,213,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM65,000$2,101,000thousands by filing date
INVITAE CORP46185L103COM250,000$2,053,000thousands by filing date
KITE PHARMA INC49803L109COM30,000$1,849,000thousands by filing date
DEXCOM INC COM252131107Stock17,000$1,392,000thousands by filing date
BLUEBIRD BIO INC09609G100COM20,000$1,284,000thousands by filing datecall
ORASURE TECHNOLOGIES INC68554V108COM170,000$1,095,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS75,000$863,000thousands by filing date
JUNO THERAPEUTICS INC48205A109COM17,500$769,000thousands by filing date
ATARA BIOTHERAPEUTICS INC COM NEW046513107Stock25,000$660,000thousands by filing date
MEDIDATE SOLUTIONS INC58471A105COM10,000$493,000thousands by filing date
TROVAGENE INC897238309COM70,000$378,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM5,000$325,000thousands by filing datecall
Foundation Medicine Inc350465100COM15,000$316,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-16-002454this filing2016-02-08acceptance time not in the bulk data set